A new report says that pharma firms are finding it difficult to recruit staff with experience in emerging scientific technologies, particularly in areas such as regulatory and quality assurance. COVID-19, Brexit and competition for talent with other countries and industry sectors are cited as key factors.

The Canadian government says stakeholders are “poised for action” to improve the collective response to medical product shortages and has come up with some questions and possible answers as to how best to go about it.

The European Medicines Agency says it is talking with international partners and pharmaceutical companies about the epidemiological situation with SARS-CoV-2 and how authorized COVID-19 vaccines can best be adapted to emerging variants.

The Canadian government says stakeholders are “poised for action” to improve the collective response to drug shortages and has come up with some questions and possible answers as to how best to go about it.

Digital health, AI, real-world evidence and “proactive learning” are key components of the EU’s proposals for new ways of regulating novel medicines, but only time will tell which products might benefit from the flexibilities offered by the “regulatory sandbox.”